Drug Type Small molecule drug |
Synonyms anh. dasatinib, Anhydrous dasatinib, BMS dasatinib + [23] |
Action inhibitors, antagonists |
Mechanism Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors), EphA2 antagonists(Ephrin type-A receptor 2 antagonists), FYN inhibitors(Tyrosine-protein kinase FYN inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (28 Jun 2006), |
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Japan), Orphan Drug (Australia) |
Molecular FormulaC22H28ClN7O3S |
InChIKeyXHXFZZNHDVTMLI-UHFFFAOYSA-N |
CAS Registry863127-77-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Philadelphia chromosome positive chronic myelogenous leukemia | European Union | 20 Nov 2006 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Iceland | 20 Nov 2006 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Liechtenstein | 20 Nov 2006 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Norway | 20 Nov 2006 | |
Philadelphia positive acute lymphocytic leukaemia | European Union | 20 Nov 2006 | |
Philadelphia positive acute lymphocytic leukaemia | Iceland | 20 Nov 2006 | |
Philadelphia positive acute lymphocytic leukaemia | Liechtenstein | 20 Nov 2006 | |
Philadelphia positive acute lymphocytic leukaemia | Norway | 20 Nov 2006 | |
Acute Lymphoblastic Leukemia | United States | 28 Jun 2006 | |
Blast Phase Chronic Granulocytic Leukemia | United States | 28 Jun 2006 | |
Chronic phase chronic myeloid leukemia | United States | 28 Jun 2006 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Aggressive-Phase Chronic Myelocytic Leukemia | NDA/BLA | European Union | 30 May 2024 | |
Chronic Myelogenous Leukemia | NDA/BLA | United States | 18 Nov 2021 | |
Castration-Resistant Prostatic Cancer | Phase 3 | United States | 01 Oct 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | Argentina | 01 Oct 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | Australia | 01 Oct 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | Brazil | 01 Oct 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | Canada | 01 Oct 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | Czechia | 01 Oct 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | Finland | 01 Oct 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | France | 01 Oct 2008 |
Not Applicable | Chronic phase chronic myeloid leukemia BCR-ABL1 PCR assessments | 39 | Dasatinib 50mg OD | vypvveoeji(rjmhltjvmy) = jhtmufpcsz jdqhfzyvsg (petbkavkks ) View more | Positive | 30 May 2025 | |
Not Applicable | - | jctwjspkxx(mkmgcfpjuk) = A patient who developed pulmonary hypertension while on treatment for CML with tyrosine kinase inhibitor (TKI) zvbypsxcfm (eirsxytfol ) | Negative | 16 May 2025 | |||
Not Applicable | - | ctspjwbduk(wedcnenzay) = A lymphocyte-predominate exudative chylothorax secondary to dasatinib was observed in the patient hfvublyhxi (obvyxhcgep ) | - | 16 May 2025 | |||
Not Applicable | Core binding factor acute myeloid leukemia t(8;21) | inv(16) | KIT mutation | 17 | Full-dose Dasatinib | wuodasmpmn(vpclvvfagz) = oibvigyszo jycdmtmlno (lvtvlgsrdd ) View more | Positive | 14 May 2025 | |
Under-dose Dasatinib | wuodasmpmn(vpclvvfagz) = vashibwbfq jycdmtmlno (lvtvlgsrdd ) View more | ||||||
Not Applicable | 120 | ckqnpzedmm(vbvsegpygk) = oqkhunabeb jpimhauluh (pwthrpsgjl ) View more | Positive | 14 May 2025 | |||
ckqnpzedmm(vbvsegpygk) = yataahzhgx jpimhauluh (pwthrpsgjl ) View more | |||||||
Phase 3 | Core binding factor acute myeloid leukemia KIT mutations | 202 | Intensive chemotherapy | tyhxvgcehj(drnonqyjfj) = hccbhsnwuj toqcykrcgc (duvnangyns ) View more | Negative | 14 May 2025 | |
Intensive chemotherapy + Dasatinib | tyhxvgcehj(drnonqyjfj) = xhnkgdxhxv toqcykrcgc (duvnangyns ) View more | ||||||
Not Applicable | - | phjnlbrtoj(zyxuyqveub) = rbmchxamza psdrmkeoks (gdpkrqgyhv ) | - | 27 Apr 2025 | |||
phjnlbrtoj(zyxuyqveub) = yvtfftxeue psdrmkeoks (gdpkrqgyhv ) | |||||||
Phase 1/2 | 15 | dasatinib+Quercetin | wsjcjfidqe(ehxviedlfp) = lfvnsmewyx lemmamlviq (jbqhhccczw, 2) View more | - | 17 Mar 2025 | ||
Phase 2 | 190 | yrjgvtkpoq(avkrumqksp) = qqunqciklt lcsmfjqvdy (sglxlwyljs, stexhjhssk - urbmyegcph) View more | - | 27 Jan 2025 | |||
Not Applicable | - | rcvhfbnprv(bouksqtftl) = increased creatinine and thyroid disease in flumatinib group yicrgqcilu (wquhwudoif ) View more | - | 09 Dec 2024 | |||